Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies

JAMA

Volumn 306, Issue 17, 2011, Pages 1874-1883

  Sorror, Mohamed L ^a,b   Sandmaier, Brenda M ^a,b   Storer, Barry E ^a,c   Franke, Georg N ^e   Laport, Ginna G ^f   Chauncey, Thomas R ^a,b,d   Agura, Edward ^g   Maziarz, Richard T ^h   Langston, Amelia ⁱ   Hari, Parameswaran ^j   Pulsipher, Michael A ^k,l   Bethge, Wolfgang ^m   Sahebi, Firoozeh ⁿ   Bruno, Benedetto ^o   Maris, Michael B ^p   Yeager, Andrew ^q   Petersen, Finn Bo ^r,s   Vindeløv, Lars ^t   McSweeney, Peter A ^p,u   Hübel, Kai ^v   Mielcarek, Marco ^a,b   Georges, George E ^a,b   Niederwieser, Dietger ^e   Blume, Karl G ^f   Maloney, David G ^a,b   Storb, Rainer ^a,b   more..

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^e UNIVERSITY OF LEIPZIG   (Germany)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Center for Applied Health Research Baylor Scott White Research Institute   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j Medical College of Wisconsin   (United States)

^k UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF UTAH   (United States)

^m UNIVERSITY OF TÜBINGEN   (Germany)

ⁿ CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^o UNIVERSITY OF TURIN   (Italy)

^p Rocky Mountain Blood and Marrow Transplant Program   (United States)

^q UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^r INTERMOUNTAIN HEALTHCARE   (United States)

^s AARHUS UNIVERSITY   (Denmark)

^t International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^u UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^v UNIVERSITY OF COLOGNE   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; BACTERIAL INFECTION; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LEUKEMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENGRAFTMENT; GRAFT REJECTION; HEMATOLOGIC MALIGNANCY; HISTOCOMPATIBILITY; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LYMPHOMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONMYELOABLATIVE CONDITIONING; ORGAN INJURY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RECURRENCE RISK; SURVIVAL TIME; TREATMENT DURATION; VIRUS INFECTION; WHOLE BODY RADIATION;

EID: 80355129623     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1558     Document Type: Article

References (38)

1. Gratwohl A, Hermans J, Goldman JM, et al. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet. 1998;352(9134):1087-1092. (Pubitemid 28448513)
2. Cancer Statistics Review SEER, 1975-2007. National Cancer Institute Web site. http://seer.cancer.gov/csr/1975-2007/. 2010, based on November 2009 SEER data submission. Accessed September 30, 2011.
3. United States Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute. United States Cancer Statistics: 1999-2005 Incidence. Centers for Disease Control and Prevention Web site. http://wonder.cdc.gov/cancer-v2005.html. 2008. Accessed September 30, 2011.
4. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97(11):3390-3400.
5. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102(6):2021-2030. (Pubitemid 37122375)
6. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091-2101.
7. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92(10):3515-3520. (Pubitemid 28525174)
8. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-2919. (Pubitemid 41510773)
9. Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2007;110(7):2744-2748. (Pubitemid 47523200)
10. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825-828.
11. Sullivan KM. Graft-vs-host disease. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation. Malden, MA: Blackwell Sciences Inc; 1999:515-536.
12. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706. (Pubitemid 29126745)
13. Couper D, Pepe MS. Modelling prevalence of a condition: chronic graft-versus-host disease after bone marrow transplantation. Stat Med. 1997;16(14):1551-1571. (Pubitemid 27341613)
14. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481-3485.
15. KeatingMJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99(10):3554-3561. (Pubitemid 34534522)
16. Vose JM, Bierman PJ, Anderson JR, et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood. 1992;80(8):2142-2148.
17. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758-2765.
18. Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007;110(13):4606-4613. (Pubitemid 351377830)
19. Fried LP, Bandeen-Roche K, Kasper JD, Guralnik JM. Association of comorbidity with disability in older women: the Women's Health and Aging Study. J Clin Epidemiol. 1999;52(1):27-37. (Pubitemid 29064271)
20. Lim Z, Brand R, Martino R, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol. 2010;28(3):405-411.
21. McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28(11):1878-1887.
22. Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116(22):4422-4429.
23. Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transpl Int. 2009;22(11):1041-1050.
24. Castermans E, Hannon M, Dutrieux J, et al. Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age. Haematologica. 2011;96(2):298-306.
25. Maris M, Boeckh M, Storer B, et al. Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Exp Hematol. 2003;31(10):941-952. (Pubitemid 37211379)
26. Kersey JH. The role of allogeneic-cell transplantation in leukemia. N Engl J Med. 2010;363(22):2158-2159.
27. Stewart BL, Storer B, Storek J, et al. Duration of immunosuppressive treatment for chronic graft-versushost disease. Blood. 2004;104(12):3501-3506. (Pubitemid 39564419)
28. Sorror ML, Leisenring W, Deeg HJ, Martin PJ, Storb R. Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia [letter]. Biol Blood Marrow Transplant. 2005;11(10):814-815. (Pubitemid 41403763)
29. Sorror ML, Leisenring W, Deeg HJ, Martin PJ, Storb R. Twenty-year follow-up in patients with aplastic anemia given marrow grafts from HLA-identical siblings and randomized to receive methotrexate/cyclosporine or methotrexate alone for prevention of graft-versus-host disease [letter]. Biol Blood Marrow Transplant. 2005;11(7):567-568. (Pubitemid 40862454)
30. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus- tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. 2005;23(9):1993-2003. (Pubitemid 46211379)
31. Rezvani AR, Storer BE, Storb RF, et al. Falling serum albumin predicts severity of acute graft-vshost disease and non-relapse mortality after non-myeloablative allogeneic hematopoietic cell transplantation [abstract 1146]. Blood. 2009;114(22):471.
32. Rotta M, Storer BE, Storb RF, et al. Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. Blood. 2010;115(6):1288-1295.
33. Sorror ML, Storer B, Sandmaier BM, Chauncey T, Storb RF, Maloney DG. Tandem autologous and nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) from HLA-matched related or unrelated donors for advanced lymphoma or chronic lymphocytic leukemia (CLL) [abstract 178]. Biol Blood Marrow Transplant. 2009;15(2)(suppl):66.
34. Böttcher S, Ritgen M, Pott C, et al. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia. 2004;18(10):1637-1645. (Pubitemid 39386342)
35. Al-Mawali A, Gillis D, Lewis I. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Am J Clin Pathol. 2009;131(1):16-26.
36. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide inmyelodysplastic syndromes. N Engl J Med. 2005;352(6):549-557.
37. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides, 2010. http://www.cibmtr.org.2010. Accessed September 30, 2011.
38. Estey E, de LimaM, Tibes R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007;109(4):1395-1400. (Pubitemid 46239569)